News Focus
News Focus
Replies to #67956 on Biotech Values
icon url

DewDiligence

10/29/08 9:40 PM

#67958 RE: rkrw #67956

GSK had an HCV polymerase inhibitor in phase-1 that was dropped in 2007.

>Wonder if they would buy vrtx?<

The $57M GSK is paying to get GNLB is barely more than round-off error.

GSK recently discontinued its share-buyback program to facilitate the financing of one or more large acquisitions.